Vivos Therapeutics, Inc. VVOS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 28.65% | -11.43% | -27.69% | -7.70% | -29.74% |
| Total Depreciation and Amortization | 12.56% | 2.71% | 15.10% | 25.49% | 72.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -108.15% | 751.33% | -305.45% | -83.92% | 7.89% |
| Change in Net Operating Assets | 290.46% | -82.49% | 244.56% | -8.27% | 304.46% |
| Cash from Operations | 47.62% | -57.66% | 8.39% | -19.09% | 7.96% |
| Capital Expenditure | -2,211.11% | 98.82% | -1,944.58% | 110.77% | -531.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -2,211.11% | 98.86% | -2,004.82% | 101.41% | -4,740.98% |
| Total Debt Issued | 16.07% | -3.31% | 447.24% | -104.32% | -- |
| Total Debt Repaid | -97.14% | -3,718.18% | 35.29% | -- | -- |
| Issuance of Common Stock | -- | 100.50% | -50.00% | 1,514.41% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 534.70% | -602.06% | 104.03% | -263.49% | -- |
| Cash from Financing | -47.16% | 40.92% | 56.89% | -75.89% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -514.81% | 107.66% | 19.54% | -163.83% | 152.58% |